December 3, 2024
Privately-held Remexian Pharma, an importer and distributor of medical cannabis of high pharmaceutical quality, is exploring ownership options advised by GCI, marketed off 2024E EBITDA of EUR 4m and revenues of EUR 20m, acc. to sources (NKP | M&A Insights Proprietary)
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights
.png){kind=logo}